Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $7.8900 (-0.63%) ($7.7700 - $8.2800) on Tue. Sep. 8, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.99% (three month average) | RSI | 42 | Latest Price | $7.8900(-0.63%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -1.9% a day on average for past five trading days. | Weekly Trend | ADAP declines -3.1% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) XLRE(26%) DRIV(23%) IWC(23%) XBI(23%) IWM(22%) | Factors Impacting ADAP price | ADAP will decline at least -1.995% in a week (0% probabilities). BNDX(-14%) TLT(-12%) BND(-9%) VXX(-8%) TIP(-8%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.995% (StdDev 3.99%) | Hourly BBV | 0 () | Intraday Trend | 1.5% | | | |
|
1 - 5 Day Possible Target | $-0.57(-107.22%) | Resistance Level | $8.31 | 5 Day Moving Average | $8.11(-2.71%) | 10 Day Moving Average | $8.23(-4.13%) | 20 Day Moving Average | $8.31(-5.05%) | To recent high | -29.2% | To recent low | 0.9% | Market Cap | $1.22b | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |